Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study

Renpei Kato¹ · Sei Naito² · Kazuyuki Numakura³ · Shingo Hatakeyama⁴ · Tomoyuki Koguchi⁵ · Takahiro Kojima⁶ · Yoshihide Kawasaki⁷ · Shuya Kandori⁶ · Sadafumi Kawamura⁸ · Yoichi Arai⁸ · Akihiro Ito⁷ · Hiroyuki Nishiyama⁶ · Yoshiyuki Kojima⁵ · Chikara Ohyama⁴ · Tomonori Habuchi³ · Norihiko Tsuchiya² · Wataru Obara¹

Received: 2 August 2021 / Accepted: 15 November 2021 / Published online: 1 January 2022
© The Author(s) 2021, corrected publication 2023

Abstract

Background This retrospective multicenter study aimed to evaluate the survival benefit of upfront cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (RCC) patients stratified by International Metastatic RCC Database Consortium (IMDC) risk criteria.

Methods We reviewed the medical records in the Michinoku Database between 2008 and 2019. Patients who received upfront CN, systemic therapy without CN (no CN) and CN after drug therapy (deferred CN) were analyzed. To exclude selection bias due to patient characteristics, baseline clinical data were adjusted by inverse probability of treatment weighting (IPTW). Overall survival (OS) was compared between upfront CN and non-upfront CN (no CN plus deferred CN). Associations between time-varying covariates including systemic therapies and OS stratified by IMDC risk criteria were analyzed by IPTW-adjusted Cox regression method.

Results Of 259 patients who fulfilled the selection criteria, 107 were classified in upfront CN and 152 in non-upfront CN group. After IPTW-adjusted analysis, upfront CN showed survival benefit compared to non-upfront CN in patients with IMDC intermediate risk (median OS: 52.5 versus 31.3 months, $p < 0.01$) and in patients with IMDC poor risk (27.2 versus 11.4 months, $p < 0.01$). In IPTW-adjusted Cox regression analysis of time-varying covariates, upfront CN was independently associated with OS benefit in patients with IMDC intermediate risk (hazard ratio 0.52, 95% confidence interval 0.29–0.93, $p = 0.03$) and in patients with IMDC poor risk (0.26, 0.11–0.59, $p < 0.01$).

Conclusions Upfront CN may confer survival benefit in RCC patients with IMDC intermediate and poor risk.

Keywords Upfront cytoreductive nephrectomy · IMDC risk · Japanese · Renal cell carcinoma

Introduction

Cytoreductive nephrectomy (CN) for metastatic RCC removes the primary kidney tumor and its potential for bleeding and pain. In addition, CN possibly eliminates the primary tumor as a potential source of immunosuppressive or tumor-promoting growth factors, thus minimizing the risk of future metastatic seeding from primary tumors [1, 2].

Based on two randomized controlled trials showing a survival advantage of nephrectomy plus interferon over

interferon alone in early 2000s [3, 4], CN became the standard of care for the management of metastatic RCC nearly 2 decades ago. Since the beginning of the targeted therapy era, the rationale for CN has been based on several retrospective studies demonstrating a survival advantage [5–7]. According to Heng et al. [8], CN is beneficial for synchronous metastatic RCC treated with targeted therapy, even after adjusting for prognostic factors. After the availability of targeted therapy, nephrectomy continued to be used in the clinical setting based on the International Metastatic RCC Database Consortium (IMDC) risk criteria. Recently, the Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) study, a phase 3 randomized controlled trial, showed no significant prolongation of OS in patients

✉ Renpei Kato
rekato@iwate-med.ac.jp

Extended author information available on the last page of the article

with initial nephrectomy followed by sunitinib compared to patients with sunitinib alone [9].

Although the CARMENA trial is a landmark study in the contemporary management of metastatic RCC, there is concern over possible recruitment bias. This trial supports upfront systemic therapy in patients with high-volume, poor-risk disease and many patients with intermediate-risk disease [9]. Moreover, the generalizability of this trial has not been assessed in a population-based database [10]. Therefore, the benefit and the role of upfront CN remain unclear.

We aimed to evaluate the survival benefit of upfront CN for metastatic RCC stratified by IMDC risk criteria, using inverse probability of treatment weighting (IPTW)-adjusted analyses in real-world clinical setting.

Materials and methods

Patients

This retrospective study was based on review of medical records in the Michinoku Database from eight institutions between January 2008 and November 2019, as reported previously [11]. The selection process of the study cohort is summarized in Fig. 1. Four hundred and thirty-two consecutive patients who had a confirmed diagnosis of metastatic RCC were enrolled. Exclusion criteria were missing follow-up, missing time to CN, inability to determine IMDC risk status, inability to determine covariate factors other than IMDC risk, IMDC favorable risk, and first-line treatment with immuno-oncology (IO) therapy or chemotherapy. Among these patients, 107 underwent upfront cytoreductive nephrectomy (CN) with or without postoperative drug therapy (upfront CN), 125 had drug therapy or observation only without CN (no CN), and 27 received subsequent CN after drug therapy (deferred CN). Patients with no CN and deferred CN were grouped into non-upfront CN group. Treatments for the subjects were planned according to standard of care in accordance with relevant treatment guidelines. The indication for upfront CN or deferred CN was decided following discussions in the surgical case conference at each institution. Clinical data including medical history, treatment duration, type of systemic therapy, and survival were extracted. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The ethical committee of each institutional approved the present study (approval number: MH2019-111). Written informed consent was waived due to the retrospective design.

Clinical outcome

Types of treatment were identified from the Michinoku database. The sequence of these treatments was

Fig. 1 Selection of study cohort from the Michinoku Database and overview of this study. Of 703 patients with renal cell carcinoma (RCC), 432 (61.5%) had synchronous metastases. After excluding 173 patients, 259 patients were studied. Among the included patients, 107 underwent upfront cytoreductive nephrectomy (CN) followed by drug therapy (upfront CN), 125 had only drug therapy or observation without CN (no CN), and 27 received CN after initial drug therapy (deferred CN). To evaluate prognostic significance of upfront CN, we performed comparison between upfront CN group and non-upfront CN group (no CN + deferred CN)

determined based on the date of CN and drug therapy initiation documented in the database. The primary outcome measure was overall survival (OS) in upfront CN and non-upfront CN groups. Subgroup analyses stratified by IMDC risk criteria were performed.

Comparison between patients with longer OS and those with shorter OS in upfront CN group

To evaluate the clinical features of patients who potentially benefit from upfront CN, we compared patients with longer OS (equal to or longer than median OS) and those with shorter OS (shorter than median OS) in upfront CN group with IMDC intermediate risk and poor risk. The clinical factors analyzed were those used for calculating IMDC risk score [Eastern Cooperative Oncology Group (ECOG) performance status (PS), hemoglobin (Hb), corrected calcium, neutrophil count, and platelet count], other known prognostic factors of CN [albumin (Alb), C-reactive protein (CRP), and neutrophil-to-lymphocyte ratio (NLR)] [8, 12–14] and number of metastases (lung, bone, liver and brain) that were not included in the propensity score model.

Statistical analysis

Fisher's exact test and t-test were used to compare patient characteristics and types of systemic therapy. Spearman's rank correlation coefficient was used to compare the time of initiation of the first systemic therapy.

To adjust for differences in baseline characteristics that may have influenced the initial treatment selection, we performed IPTW based on the propensity to receive upfront CN versus non-upfront CN, which was estimated by logistic regression. Supplementary Table 1 shows the variables included. These variables were selected based on their association with age-sex-specific mortality and cancer-specific mortality [15–18]. The covariate balance was assessed by standardized differences. A standardized difference < 0.1 was considered a negligible difference in the mean or prevalence of a covariate between two groups [19].

OS was calculated from the date of diagnosis of metastatic RCC to the date of all-cause death or date of the last follow-up. Survival curves were constructed using the Kaplan–Meier method and analyzed by the log-rank test. In addition, an IPTW-adjusted Cox proportional hazard regression analysis was performed to estimate the prognostic significance of time-varying covariates including systemic treatments [20]. Correlation between outcome and

the variables is expressed as hazard ratio (HR) and 95% confidence interval (CI). In upfront CN group with IMDC intermediate and poor risk, clinical parameters were compared between patients with longer OS and those with shorter OS by Fisher's exact test and t-test. All statistical analyses were conducted using JMP 14.3.0 (SAS Institute, Cary, NC).

Results

Patients' characteristics and outcome in all subjects

Two hundred and fifty-nine patients fulfilled the selection criteria in this study (Fig. 1). To evaluate the clinical significance of upfront CN, we divided all patients into an upfront CN group ($n = 107$) and a non-upfront CN group (no CN and deferred CN; $n = 152$). Median follow-up period was 21.3 months (range, 0.2–147.6).

Patient characteristics of the two groups are summarized in Table 1. Patients who underwent upfront CN were younger, with lower proportions of IMDC poor risk, ECOG PS 1 or higher, clinical T3 and T4 primary tumors, cN1 disease and liver metastasis. The proportions of patients treated with cytokine therapy, subsequent nivolumab monotherapy and metastasectomy were higher in upfront CN group than in non-upfront CN group. Drugs used as first-line therapy are

Table 1 Patient characteristics of study groups

Characteristics	Upfront CN $n = 107$	Non-upfront CN $n = 152$	p value
Age, mean $\pm$ SD (years)	64.2 $\pm$ 1.0	67.0 $\pm$ 0.9	0.03
Sex (men), n (%)	77 (72.0)	110 (72.4)	1.00
IMDC intermediate / poor risk, n	70 / 37	57 / 95	< 0.01
ECOG PS $\geq$ 1, n (%)	30 (28.0)	74 (48.7)	< 0.01
T stage cT3 / 4, n (%)	63 (58.9)	116 (76.3)	< 0.01
N stage cN1 / 2, n (%)	31 (29.0)	71 (46.7)	< 0.01
M stage cM1, n (%)	99 (92.5)	141 (92.8)	1.00
Metastatic sites, n (%)			
Lung	72 (67.3)	100 (65.8)	0.89
Bone	33 (30.8)	49 (32.2)	0.89
Liver	9 (8.4)	27 (17.8)	0.04
Brain	8 (7.5)	13 (8.6)	0.82
Lymph node	35 (32.7)	55 (36.2)	0.60
First line drug therapy,			
Cytokine /targeted therapy / none, n	20 / 81 / 6	6 / 141 / 5	< 0.01
Subsequent NIVO monotherapy	36 (33.6)	20 (13.2)	< 0.01
Metastasectomy, n (%)	23 (21.5)	11 (7.2)	< 0.01
RT for bone metastases, n (%)	26 (24.3)	24 (15.8)	0.11
RT for brain metastases, n (%)	12 (11.2)	10 (6.6)	0.26

CN Cytoreductive nephrectomy, IMDC the International Metastatic RCC Database Consortium, ECOG PS ECOG performance status, NIVO nivolumab, RT radiation therapy

Table 2 Baseline characteristics of all patients divided into upfront CN group and non-upfront CN group: unadjusted and IPTW-adjusted cohorts

Characteristics	Unadjusted cohort			IPTW-adjusted cohort		
	Upfront CN <i>n</i> = 107	Non-upfront CN <i>n</i> = 152	Std diff	Upfront CN <i>n</i> = 267	Non-upfront CN <i>n</i> = 254	Std diff
Age, mean ± SD (year)	64.2 ± 1.0	67.0 ± 0.9	0.27	65.6 ± 0.6	65.9 ± 0.7	0.03
Sex (men), <i>n</i> (%)	77 (72.0)	110 (72.4)	0.01	191 (71.3)	183 (72.2)	0.01
IMDC poor risk, <i>n</i> (%)	37 (34.6)	95 (62.5)	0.56	144 (53.8)	133 (52.4)	0.03
ECOG PS ≥ 1, <i>n</i> (%)	30 (28.0)	74 (48.7)	0.53	113 (42.4)	105 (41.2)	0.03
T stage cT3/4, <i>n</i> (%)	63 (58.9)	116 (76.3)	0.26	191 (71.3)	180 (71.1)	0.00
N stage cN1/2, <i>n</i> (%)	31 (29.0)	71 (46.7)	0.46	120 (44.7)	106 (41.8)	0.07
M stage cM1, <i>n</i> (%)	99 (92.5)	141 (92.8)	0.00	248 (92.9)	236 (93.0)	0.00
Metastatic sites, <i>n</i> (%)						
Lung	72 (67.3)	100 (65.8)	0.02	182 (68.0)	168 (66.1)	0.03
Bone	33 (30.8)	49 (32.2)	0.05	78 (29.2)	79 (31.2)	0.07
Liver	9 (8.4)	27 (17.8)	0.70	39 (14.5)	36 (14.4)	0.01
Brain	8 (7.5)	13 (8.6)	0.15	16 (6.0)	18 (7.1)	0.18
Lymph node	35 (32.7)	55 (36.2)	0.10	99 (37.1)	89 (35.1)	0.06

IPTW inverse probability of treatment weighting, *CN* cytoreductive nephrectomy, *IMDC* the International Metastatic RCC Database Consortium, *ECOG PS* ECOG performance status, *Std diff* standardized difference

Fig. 2 IPTW-adjusted overall survival (OS) in all subjects. Red curve represents non-upfront CN group, and blue curve represents upfront CN group. IPTW-adjusted OS is significantly longer in upfront CN group than in non-upfront CN group [36.1 (32.6–45.1) months versus 20.4 (15.6–26.0) months; $p < 0.01$]. CN; cytoreductive nephrectomy, IPTW; inverse probability of treatment weighting

summarized in Supplementary Table 2. The most frequently used targeted therapy was sunitinib, and the most frequently used cytokine therapy was interferon monotherapy. After IPTW adjustment, the baseline cohort characteristics were balanced except for the proportion of patients with brain metastasis (Table 2, Supplementary Fig. 1A and B).

Figure 2 shows IPTW-adjusted OS of upfront CN and non-upfront CN groups. The upfront CN group showed significantly longer OS compared to non-upfront CN group after IPTW adjustment of baseline characteristics [median OS: 36.1 (95% CI 32.6–45.1) months versus 20.4 (95% CI 15.6–26.0) months, $p < 0.01$] (Fig. 2). Analysis using unadjusted baseline characteristics also yielded

significantly longer OS in upfront CN group compared to non-upfront CN group (Supplementary Fig. 2). Year of initiation of the first therapy was similar between the two groups (Supplementary Fig. 3).

Subgroup analyses stratified by IMDC risk criteria

Clinical characteristics of patients with IMDC intermediate risk are summarized in Table 3. In this subgroup, patients who underwent upfront CN had less IMDC risk factors, and lower proportions of clinical T3 and T4 primary tumors, cN1 disease, and liver metastasis. After IPTW adjustment, the baseline cohort characteristics were balanced except for the proportions of patients with ECOG PS 1 or higher and brain metastasis (Table 3). Upfront CN was associated with significantly longer OS compared to non-upfront CN after IPTW adjustment of baseline characteristics [median OS: 52.5 (95% CI 42.1–63.4) months versus 31.3 (95% CI 28.1–38.5) months, $p < 0.01$] (Fig. 3).

Clinical characteristics of patients with IMDC poor risk are summarized in Table 4. There were no significant differences in patient characteristics between the two groups. After IPTW adjustment, the baseline cohort characteristics were balanced except for the proportions of patients with liver and brain metastases (Table 4). Upfront CN was associated with significantly longer OS compared to non-upfront CN after IPTW adjustment of baseline characteristics [median OS: 27.2 (95% CI 11.9–36.1) months versus 11.4 (95% CI 10.4–15.7) months, $p < 0.01$] (Fig. 3).

In both IMDC intermediate and poor risk patients, analysis with unadjusted baseline characteristics also showed

Table 3 Baseline characteristics of patients with IMDC intermediate risk divided into upfront CN group and non-upfront CN group: unadjusted and IPTW-adjusted cohorts

Characteristics	Unadjusted cohort			IPTW-adjusted cohort			
	Upfront CN <i>n</i> = 70	Non-upfront CN <i>n</i> = 57	<i>p</i> value	Std diff	Upfront CN <i>n</i> = 125	Non-upfront CN <i>n</i> = 125	Std diff
Age, mean ± SD (year)	63.6 ± 1.3	67.3 ± 1.5	0.06	0.34	64.3 ± 1.0	64.9 ± 1.1	0.05
Sex (men), <i>n</i> (%)	48 (68.6)	42 (73.7)	0.56	0.07	87 (69.8)	86 (68.8)	0.01
Number of IMDC risk:							
2 risks, <i>n</i> (%)	38 (54.3)	42 (73.7)	0.03	0.30	77 (62.0)	78 (62.7)	0.01
ECOG PS ≥ 1, <i>n</i> (%)	10 (14.3)	8 (14.0)	1.00	0.02	18 (14.3)	20 (16.3)	0.13
T stage cT3b/3c/4, <i>n</i> (%)	37 (52.9)	43 (75.4)	0.01	0.35	80 (64.0)	87 (69.9)	0.09
N stage cN1/2, <i>n</i> (%)	13 (18.6)	25 (43.9)	<0.01	0.76	37 (29.9)	40 (31.9)	0.07
M stage cM1, <i>n</i> (%)	65 (92.9)	51 (89.5)	0.54	0.04	116 (93.1)	116 (92.9)	0.00
Metastatic sites, <i>n</i> (%)							
Lung	46 (65.7)	38 (66.7)	1.00	0.02	84 (67.7)	80 (64.3)	0.05
Bone	23 (32.9)	12 (21.1)	0.16	0.43	36 (28.9)	38 (30.3)	0.05
Liver	4 (5.7)	10 (17.5)	0.04	0.94	13 (10.2)	13 (10.7)	0.05
Brain	5 (7.1)	1 (1.8)	0.22	1.12	6 (4.6)	3 (2.1)	0.81
Lymph node	17 (24.3)	19 (33.3)	0.32	0.31	33 (26.1)	36 (28.9)	0.10

IPTW inverse probability of treatment weighting, *CN* cytoreductive nephrectomy, *IMDC* the International Metastatic RCC Database Consortium, *ECOG PS* ECOG performance status, *Std diff* standardized difference

Fig. 3 IPTW-adjusted overall survival (OS) in patients with IMDC intermediate or poor risk. Red curve represents non-upfront CN group, and blue curve represents upfront CN group. IMDC intermediate risk subgroup: IPTW-adjusted OS is significantly longer in the upfront CN group than in the non-upfront CN group [52.5 (42.1–63.4) months versus 31.3 (28.1–38.5) months; $p < 0.01$]. IMDC poor risk group: IPTW-adjusted OS is significantly longer in the upfront CN group than in the non-upfront CN group [27.2 (11.9–36.1) months versus 11.4 (10.4–15.7) months; $p < 0.01$]. *CN* cytoreductive nephrectomy, *IPTW* inverse probability of treatment weighting

significantly longer OS in the upfront CN group than in the non-upfront CN group (Supplementary Fig. 4).

Association of upfront CN and other systemic therapies with survival

The upfront CN and non-upfront CN groups differed significantly not only in baseline characteristics but also in the use of some systemic therapies (Table 1, Supplementary Table 3). In the subgroup with IMDC intermediate risk, the proportions of patients treated with cytokine therapy, subsequent nivolumab monotherapy, metastasectomy and radiotherapy for brain metastasis were higher in upfront CN group than in non-upfront CN. In the subgroup with IMDC poor risk, the proportion of patients treated with cytokine therapy and subsequent nivolumab monotherapy was higher in upfront CN than in non-upfront CN. Given these differences in systemic treatment, we performed an IPTW-adjusted Cox regression analysis to estimate the prognostic significance of time-varying covariates including systemic treatments.

In the subgroup with IMDC intermediate risk, univariate and multivariate analyses of IPTW-adjusted cohort identified upfront CN versus no CN as an independent factor associated with prolonged OS, and older age and clinical T3 and T4 primary tumors as independent factors associated with shortened OS (Supplementary Table 4).

In the subgroup with IMDC poor risk, univariate and multivariate analyses of IPTW-adjusted cohort identified

Table 4 Baseline characteristics of patients with IMDC poor risk divided into upfront CN group and non-upfront CN group: unadjusted and IPTW-adjusted cohorts

Characteristics	Unadjusted cohort				IPTW-adjusted cohort		
	Upfront CN <i>n</i> = 37	Non-upfront CN <i>n</i> = 95	<i>p</i> value	Std diff	Upfront CN <i>n</i> = 132	Non-upfront CN <i>n</i> = 131	Std diff
Age, mean ± SD (year)	65.3 ± 1.3	66.9 ± 1.0	0.36	0.18	66.4 ± 0.7	66.4 ± 0.9	0.00
Sex (men), <i>n</i> (%)	29 (78.4)	68 (71.6)	0.51	0.09	94 (71.2)	96 (73.2)	0.03
Number of IMDC risk: ≥ 4 risks, <i>n</i> (%)	16 (43.2)	46 (48.4)	0.70	0.11	59 (45.0)	62 (47.2)	0.05
ECOG PS ≥ 1, <i>n</i> (%)	20 (54.1)	66 (69.5)	0.11	0.25	90 (68.3)	87 (66.3)	0.03
T stage cT3b/3c/4, <i>n</i> (%)	26 (70.3)	73 (76.8)	0.50	0.09	100 (75.8)	99 (75.5)	0.00
N stage cN1/2, <i>n</i> (%)	18 (48.7)	46 (48.4)	1.00	0.01	69 (52.0)	65 (49.4)	0.05
M stage cM1, <i>n</i> (%)	34 (91.9)	90 (94.7)	0.69	0.03	125 (94.6)	124 (94.3)	0.00
Metastatic sites, <i>n</i> (%)							
Lung	26 (70.3)	62 (65.3)	0.68	0.07	94 (71.5)	88 (67.1)	0.06
Bone	10 (27.0)	37 (39.0)	0.23	0.36	46 (34.7)	47 (36.1)	0.04
Liver	5 (13.5)	17 (17.9)	0.61	0.29	19 (14.2)	22 (16.7)	0.17
Brain	3 (8.1)	12 (12.6)	0.56	0.45	12 (8.8)	15 (11.3)	0.26
Lymph node	18 (48.7)	36 (37.9)	0.32	0.25	56 (42.0)	54 (41.4)	0.01

IPTW inverse probability of treatment weighting, *CN* cytoreductive nephrectomy, *IMDC* the International Metastatic RCC Database Consortium, *ECOG PS* ECOG performance status, *Std diff* standardized difference

Table 5 IPTW-adjusted univariate and multivariate Cox regression analyses for systemic therapies predicting overall survival in IMDC poor risk group

Covariates		Univariate analysis			Multivariate analysis		
		HR	95% CI	<i>p</i> value	HR	95% CI	<i>p</i> value
Age	≥ 75 vs 75 >	1.08	0.57–2.03	0.82	1.13	0.40–3.19	0.82
Sex	Men vs Female	0.66	0.42–1.05	0.08	0.50	0.20–1.24	0.14
Number of IMDC risk:	≥ 4 risks vs 3 risks	0.69	0.40–1.21	0.20	0.35	0.13–0.95	0.04
ECOG PS	≥ 1 vs 0	1.25	0.78–1.99	0.36	1.28	0.60–2.72	0.52
T stage	≥ cT3 vs cT2 ≥	1.12	0.67–1.87	0.66	0.67	0.31–1.43	0.30
N stage	cN1/2 vs cN0	1.65	1.04–2.61	0.03	0.92	0.38–2.21	0.85
M stage	cM1 vs cM0	0.58	0.17–1.95	0.38	0.24	0.05–1.17	0.08
Metastatic sites							
Lung	Yes vs No	1.26	0.78–2.04	0.34	1.21	0.55–2.69	0.63
Bone	Yes vs No	1.42	0.78–2.61	0.25	4.98	1.77–14.0	<0.01
Liver	Yes vs No	0.77	0.38–1.56	0.47	0.42	0.13–1.44	0.17
Brain	Yes vs No	1.92	0.86–4.29	0.11	4.32	1.14–16.4	0.03
Lymph node	Yes vs No	0.93	0.57–1.51	0.76	3.02	1.24–7.36	0.02
CN							
	U-CN vs No-CN	0.45	0.25–0.81	<0.01	0.22	0.09–0.50	<0.01
	U-CN vs D-CN	1.01	0.54–1.88	0.97	0.41	0.14–1.23	0.11
	D-CN vs No-CN	0.45	0.21–0.95	0.04	0.53	0.17–1.66	0.27
First line drug therapy	Cy vs TT	0.73	0.23–2.36	0.60	3.03	0.61–15.0	0.17
Subsequent NIVO monotherapy	Yes vs No	0.95	0.56–1.59	0.83	1.80	0.74–4.36	0.20
Metastasectomy	Yes vs No	0.37	0.16–0.87	0.02	0.11	0.02–0.54	<0.01
RT for bone metastases	Yes vs No	0.42	0.16–1.10	0.08	0.20	0.06–0.68	<0.01
RT for brain metastases	Yes vs No	1.00	0.29–3.49	0.99	0.64	0.07–5.68	0.69

U-CN upfront cytoreductive nephrectomy, *D-CN* deferred cytoreductive nephrectomy, *No-CN* no cytoreductive nephrectomy, *Cy* cytokine therapy, *TT* targeted therapy, *NIVO* nivolumab, *RT* radiation therapy, *N.D.* not detected

upfront CN versus no CN and metastasectomy as independently associated with prolonged OS (Table 5).

Clinical features of patients with longer OS versus shorter OS in upfront CN group

To evaluate the clinical features of IMDC intermediate and poor risk patients who potentially benefit from upfront CN, we analyzed the IMDC risk factors, other known prognostic factors of CN and number of metastatic sites not included in propensity score model (Table 6). In IPTW-adjusted cohort with IMDC intermediate risk, mean number of lung metastases was significantly smaller in patients with longer OS

than in those with shorter OS (1.7 ± 0.3 versus 3.2 ± 0.3 , $p < 0.01$).

In IPTW-adjusted cohort with IMDC poor risk, mean Hb level was significantly lower (10.6 ± 0.2 versus 11.3 ± 0.2 mg/dL, $p < 0.01$) and mean albumin-corrected calcium level was also significantly lower (3.0 ± 0.1 versus 3.4 ± 0.1 mg/dL, $p < 0.01$) in patients with longer OS than in those with shorter OS. Mean CRP was significantly higher for longer OS than for shorter OS (7.7 ± 0.80 versus 5.4 ± 0.6 mg/dL, $p = 0.02$). Mean number of bone metastases was significantly smaller for longer OS than for shorter OS (0.1 ± 0.1 versus 1.2 ± 0.2 , $p < 0.01$).

Table 6 Comparison of clinical features between patients with longer overall survival (OS) and those with shorter OS in the upfront cytoreductive nephrectomy group

	Unadjusted cohort			IPTW-adjusted cohort		
	Longer OS	Shorter OS	<i>p</i> value	Longer OS	Shorter OS	<i>p</i> value
IMDC intermediate risk						
ECOG PS ≥ 2 , n (%)	2 (5.7)	2 (5.7)	1.00	3 (5.1)	4 (6.2)	0.77
Hb, mean $\pm$ SD (g/dL)	13.9 ± 0.3	13.1 ± 0.5	0.20	13.8 ± 0.2	13.0 ± 0.4	0.08
Corrected calcium, mean $\pm$ SD (mg/dL)	9.1 ± 0.1	9.1 ± 0.1	1.00	9.1 ± 0.1	9.1 ± 0.1	0.86
Neutrophil count, mean $\pm$ SD ($\times 10^3/\mu\text{L}$)	4.3 ± 0.2	4.3 ± 0.3	0.96	4.2 ± 0.1	4.3 ± 0.2	0.73
Platelet count, mean $\pm$ SD ($\times 10^4/\mu\text{L}$)	24.1 ± 0.1	24.3 ± 0.1	0.91	23.8 ± 0.1	24.4 ± 0.1	0.67
Alb, mean $\pm$ SD (g/dL)	4.1 ± 0.1	4.0 ± 0.1	0.42	4.1 ± 0.1	3.9 ± 0.1	0.16
CRP, mean $\pm$ SD (mg/dL)	1.5 ± 0.4	2.3 ± 0.7	0.35	1.4 ± 0.3	2.4 ± 0.5	0.08
NLR, mean $\pm$ SD	2.8 ± 0.2	2.9 ± 0.2	0.85	2.8 ± 0.1	2.9 ± 0.2	0.50
Number of metastases, mean $\pm$ SD						
Lung	1.9 ± 0.4	3.0 ± 0.4	0.06	1.7 ± 0.3	3.2 ± 0.3	< 0.01
Bone	0.7 ± 0.2	0.7 ± 0.3	0.92	0.7 ± 0.1	0.7 ± 0.2	0.93
Liver	0.2 ± 0.2	0.2 ± 0.2	0.79	0.2 ± 0.1	0.3 ± 0.1	0.96
Brain	0.1 ± 0.1	0.2 ± 0.1	0.31	0.1 ± 0.0	0.1 ± 0.1	0.30
IMDC poor risk						
ECOG PS ≥ 2 , n (%)	3 (16.7)	2 (10.5)	0.66	15 (20.5)	7 (9.3)	0.16
Hb, mean $\pm$ SD (g/dL)	10.6 ± 0.4	11.1 ± 0.4	0.35	10.6 ± 0.2	11.3 ± 0.2	< 0.01
Corrected calcium, mean $\pm$ SD (mg/dL)	9.7 ± 0.3	9.5 ± 0.2	0.55	9.7 ± 0.1	9.7 ± 0.1	0.89
Neutrophil count, mean $\pm$ SD ($\times 10^3/\mu\text{L}$)	4.6 ± 0.4	5.6 ± 0.5	0.16	4.7 ± 0.2	5.4 ± 0.3	0.08
Platelet count, mean $\pm$ SD ($\times 10^4/\mu\text{L}$)	37.0 ± 0.3	33.6 ± 0.2	0.40	35.6 ± 0.1	33.2 ± 0.1	0.22
Alb, mean $\pm$ SD (g/dL)	3.0 ± 0.2	3.3 ± 0.1	0.15	3.0 ± 0.1	3.4 ± 0.1	< 0.01
CRP, mean $\pm$ SD (mg/dL)	7.9 ± 1.7	6.4 ± 1.3	0.50	7.7 ± 0.8	5.4 ± 0.6	0.02
NLR, mean $\pm$ SD	2.8 ± 0.2	2.9 ± 0.2	0.85	2.8 ± 0.1	2.9 ± 0.2	0.50
Number of metastases, mean $\pm$ SD						
Lung	2.4 ± 0.6	2.3 ± 0.5	0.90	2.3 ± 0.3	2.2 ± 0.2	0.94
Bone	0.1 ± 0.1	1.1 ± 0.4	0.02	0.1 ± 0.0	1.2 ± 0.2	< 0.01
Liver	0.4 ± 0.3	0.1 ± 0.1	0.33	0.5 ± 0.1	0.2 ± 0.0	0.12
Brain	0.1 ± 0.1	0.1 ± 0.1	0.50	0.1 ± 0.0	0.0 ± 0.0	0.42

Longer OS; $\geq$ median OS, Shorter OS; $<$ median OS, IPTW inverse probability of treatment weighting, IMDC the International Metastatic RCC Database Consortium, CN cytoreductive nephrectomy, ECOG PS ECOG performance status, Hb hemoglobin, Alb albumin, CRP C-reactive protein, NLR neutrophil-to-lymphocyte ratio, SD standard deviation

Discussion

Our study using IPTW analysis demonstrated that upfront CN confers survival benefit in patients with IMDC intermediate and poor risk. For patients diagnosed with metastatic RCC, a multidisciplinary conference to decide treatment options should be conducted, including discussions on whether CN is likely to provide survival benefit.

The CARMENA trial reported no significant prolongation of OS in patients who received initial nephrectomy followed by sunitinib compared to patients with sunitinib alone. Although the CARMENA trial is an important and commendable effort to evaluate the impact of CN in patients with metastatic RCC, it should be evaluated within the context of its limitations [1]. Recently, our group reported that CN conferred survival benefit in metastatic RCC patients treated with targeted therapy using IPTW analysis. In that study, OS in patients treated with upfront CN was significantly longer than in those without CN. Patients treated with deferred CN also had prolonged OS compared with those without CN [11]. In the clinical setting, deferred CN is often selected for patients who has achieved good response to first-line drug therapy. The no-CN group included patients who planned deferred CN at the start of first-line therapy, but continued drug therapy because of insufficient response. In the present study, we aimed to verify whether CN or drug therapy should be selected as the first-line therapy by performing analyses comparing patients with upfront CN and those with no CN + deferred CN. In this study, the upfront CN group had more patients treated with cytokine therapy than the no CN group. Naito, et al. [21] showed that cytokine therapy conferred survival benefit in Japanese RCC patients. Based on this evidence, cytokine therapy has been used as standard of care for eligible patients in the era of targeted therapy in Japan. Hence, inclusion of patients on targeted therapy and those on cytokine therapy is important to verify the benefit of upfront CN with respect to IMDC risk in the real-world clinical setting in Japan.

The present study demonstrated that upfront CN confers survival benefit in patients with IMDC intermediate or poor risk, even after adjusting for baseline patient characteristics. IPTW-adjusted Cox regression analyses in patients with IMDC intermediate risk showed that ECOG PS 1 or higher and the presence of brain metastasis were not associated with worse OS. Furthermore, the presence of brain or liver metastasis was not associated with worse OS in IPTW-adjusted Cox regression analyses in patients with IMDC poor risk. However, the OS curve of patients with IMDC poor risk decreased steeply within 12 months (Fig. 3D). We consider that patients with IMDC poor risk who are expected to survive less than 12 months may have marginal benefit from upfront CN.

The present study showed differences in the proportions of patients using systemic therapies other than CN between upfront CN and non-upfront CN groups, after adjusting patient characteristics. In RCC patients, targeted therapy prolonged survival compared with cytokine therapy [22], and local therapy by metastasectomy and radiation therapy for bone or brain metastasis improved clinical outcome [23–28]. To verify whether other systemic therapies contributed to the prolonged OS observed with upfront CN, we performed multivariate analysis including upfront CN and other systemic therapies in IPTW-adjusted Cox proportional hazard regression models. In the subgroup with IMDC intermediate risk, upfront CN versus no CN was identified as an independent factor predicting OS prolongation, while other systemic therapies were not associated with OS. Therefore, the option of upfront CN should be considered at the beginning of treatment in patients with IMDC intermediate risk. In patients with IMDC poor risk, upfront CN versus no CN and metastasectomy were independently associated with OS benefit. Therefore, upfront CN may also be indicated in metastatic RCC patients with IMDC poor risk.

To evaluate the clinical features of patients who potentially benefit from upfront CN, we analyzed factors including IMDC risk factors and other known prognostic factors of CN [8, 12–14]. In our analysis of upfront CN group with IMDC intermediate risk, patients with longer OS had less lung metastases. In patients with IMDC intermediate risk who had small volume of lung metastases, targeted therapy subsequent to upfront CN may bring survival benefit. On the other hand, in our analysis of upfront CN group with IMDC poor risk, IPTW-adjusted cohort with longer OS showed significantly lower Hb, lower albumin level, and higher CRP level compared to those with shorter OS. However, all these factors did not differ significantly between the longer and shorter OS groups in IPTW-unadjusted cohort. These differences between IPTW-unadjusted cohort and IPTW-adjusted cohort may be due to overweighted effects of minority group by IPTW analysis. In both IPTW-unadjusted and -adjusted analyses, patients with shorter OS had more bone metastases than patients with longer OS. As reported previously, the presence of bone metastases is an unfavorable prognostic factor [29]. Indications for upfront CN in patients with IMDC poor risk have not yet been established. The present analysis suggests that IMDC poor risk patients who have multiple bone metastases may not benefit from upfront CN in terms of overall survival. Refining the risk stratification model is crucial for determining which patient may benefit from upfront CN. IO combination therapy prolonged progression-free survival and OS in patients with bone metastases compared with sunitinib [30]. Further study is required to evaluate the survival benefit of upfront CN in IMDC poor risk patients with bone metastases in the IO therapy era.

Recent studies have demonstrated that institutional experience is associated with improved outcomes [31, 32]. In our study, most participating institutions are academic centers. This may be one of the factors that contributed to better survival with upfront CN.

Our study had several limitations. First, it was a retrospective study with a small sample size and potential selection bias. Even though we performed IPTW-adjusted analyses, this could not control several unmeasured confounders. Second, the indication for upfront CN was not uniform among the participating institutions. Third, we excluded patients treated with first-line IO therapy, because only one patient had IO therapy. Finally, the IPTW method has overweighted effects of minority group, resulting in an adjusted cohort that differs to a great extent from the median patient characteristics. Further study is required to evaluate the survival benefit of upfront CN followed by IO therapy compared to IO therapy alone. Nevertheless, to the best of our knowledge, this is the first report on the prognostic significance of upfront CN stratified by IMDC risk criteria, using IPTW-adjusted analysis. Nowadays, IO combination therapies have become the standard of care for metastatic RCC patients. These novel agents are expected to prolong survival after upfront CN.

In conclusion, our study found that upfront CN conferred survival benefit in Japanese patients with IMDC intermediate and poor risk. Careful patient selection is warranted to determine if a patient will benefit from CN.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s10147-021-02091-8>.

Acknowledgements The authors would like to thank Koji Mitsuzuka, Shintaro Narita, Hayato Yamamoto, Toshihiko Sakurai, Yuki Fujita, Yukie Nishizawa and Satomi Sakamoto for their invaluable support with data collection, and Fumiaki Takahashi for his invaluable support with statistical analysis.

Author contributions Conception and design of the study: RK, WO. Analysis and interpretation of data: RK. Collection and assembly of data: RK, SN, KN, SH, TK, TK, YK, SK, SK, YA, AI, YK, TH, NT, HN, WO. Drafting of the article: RK. Critical revision of the article for important intellectual content: WO, YA, AI, YK, CO, TH, NT, HN. All other authors have contributed to data collection and interpretation, and critically reviewed the manuscript. All authors approved the final version of the manuscript, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding This study was supported by grants from the Matching Fund Subsidy for Private Universities. None of the funding sources had any role in the study design, data collection/analyses, interpretation of data, or writing of the manuscript.

Declarations

Conflicts of interest All authors declare no potential conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Motzer RJ, Russo P (2018) Cytoreductive nephrectomy - patient selection is key. *N Engl J Med* 379:481–482
2. Turajlic S, Xu H, Litchfield K et al (2018) Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. *Cell* 173:581–594.e512
3. Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. *N Engl J Med* 345:1655–1659
4. Mickisch GH, Garin A, van Poppel H et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. *Lancet* 358:966–970
5. Choueiri TK, Xie W, Kollmannsberger C et al (2011) The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. *J Urol* 185:60–66
6. Bhindi B, Abel EJ, Albiges L et al (2019) Systematic review of the role of cytoreductive nephrectomy in the targeted therapy era and beyond: an individualized approach to metastatic renal cell carcinoma. *Eur Urol* 75:111–128
7. Hanna N, Sun M, Meyer CP et al (2016) Survival analyses of patients with metastatic renal cancer treated with targeted therapy with or without cytoreductive nephrectomy: a national cancer data base study. *J Clin Oncol* 34:3267–3275
8. Heng DY, Wells JC, Rini BI et al (2014) Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium. *Eur Urol* 66:704–710
9. Méjean A, Ravaud A, Thezenas S et al (2018) Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. *N Engl J Med* 379:417–427
10. Arora S, Sood A, Dalela D et al (2019) Cytoreductive nephrectomy: assessing the generalizability of the CARMENA trial to real-world national cancer data base cases. *Eur Urol* 75:352–353
11. Hatakeyama S, Naito S, Numakura K et al (2020) Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A. *Int J Urol*. <https://doi.org/10.1111/iju.14466>
12. Tatsugami K, Shinohara N, Kondo T et al (2015) Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era. *Int J Urol* 22:736–740
13. Shuch B, La Rochelle JC, Wu J et al (2008) Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. *Cancer* 113:1324–1331

14. McIntosh AG, Umbreit EC, Holland LC et al (2020) Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. *Cancer* 126:3950–3960
15. Dicker D, Nguyen G, Abate D et al (2018) Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392:1684–1735
16. Paner GP, Stadler WM, Hansel DE et al (2018) Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. *Eur Urol* 73: 560–569
17. Bianchi M, Sun M, Jeldres C et al (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol* 23:973–980
18. Ko JJ, Xie W, Kroeger N et al (2015) The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. *Lancet Oncol* 16:293–300
19. Austin PC (2011) An Introduction to propensity score methods for reducing the effects of confounding in observational studies. *Multivar Behav Res* 46:399–424
20. Seisen T, Sun M, Lipsitz SR et al (2017) Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder. *Eur Urol* 72:483–487
21. Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. *Eur Urol* 57:317–325
22. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol* 27:3584–3590
23. Vogl U, Zehetgruber H, Dominkus M et al (2006) Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. *Br J Cancer* 95:691–698
24. Alt AL, Boorjian SA, Lohse CM et al (2011) Survival after complete surgical resection of multiple metastases from renal cell carcinoma. *Cancer* 117:2873–2882
25. Zaid HB, Parker WP, Safdar NS et al (2017) Outcomes following complete surgical metastasectomy for patients with metastatic renal cell carcinoma: a systematic review and meta-analysis. *J Urol* 197:44–49
26. Dabestani S, Marconi L, Hofmann F et al (2014) Local treatments for metastases of renal cell carcinoma: a systematic review. *Lancet Oncol* 15:E549–E561
27. Sperduto PW, Chao ST, Sneed PK et al (2010) Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. *Int J Radiat Oncol Biol Phys* 77:655–661
28. Sheehan JP, Sun MH, Kondziolka D et al (2003) Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. *J Neurosurg* 98:342–349
29. McKay RR, Kroeger N, Xie W et al (2014) Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. *Eur Urol* 65:577–584
30. Choueiri TK, Powles T, Burotto M et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. *N Engl J Med* 384:829–841
31. Joshi SS, Handorf EA, Zibelman M et al (2018) Treatment facility volume and survival in patients with metastatic renal cell carcinoma: a registry-based analysis. *Eur Urol* 74:387–393
32. Bhindi B, Habermann EB, Mason RJ et al (2018) Comparative survival following initial cytoreductive nephrectomy versus initial targeted therapy for metastatic renal cell carcinoma. *J Urol* 200:528–534

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Renpei Kato¹ · Sei Naito² · Kazuyuki Numakura³ · Shingo Hatakeyama⁴ · Tomoyuki Koguchi⁵ · Takahiro Kojima⁶ · Yoshihide Kawasaki⁷ · Shuya Kandori⁶ · Sadafumi Kawamura⁸ · Yoichi Arai⁸ · Akihiro Ito⁷ · Hiroyuki Nishiyama⁶ · Yoshiyuki Kojima⁵ · Chikara Ohyama⁴ · Tomonori Habuchi³ · Norihiko Tsuchiya² · Wataru Obara¹

Sei Naito
seinaitoh@yahoo.ne.jp

Kazuyuki Numakura
numakura@doc.med.akita-u.ac.jp

Shingo Hatakeyama
shingoh@hirosaki-u.ac.jp

Tomoyuki Koguchi
gucchii@gmail.com

Takahiro Kojima
tkojima@md.tsukuba.ac.jp

Yoshihide Kawasaki
kawasaki@uro.med.tohoku.ac.jp

Shuya Kandori
shuya79@md.tsukuba.ac.jp

Sadafumi Kawamura
kawamura-sa889@miyagi-pho.jp

Yoichi Arai
yarai@uro.med.tohoku.ac.jp

Akihiro Ito
itoaki@uro.med.tohoku.ac.jp

Hiroyuki Nishiyama
nishiuro@gmail.com

Yoshiyuki Kojima
ykojima@fmu.ac.jp

Chikara Ohyama
coyama@hirosaki-u.ac.jp

Tomonori Habuchi
thabuchi@gmail.com

Norihiko Tsuchiya
ntsuchiya@med.id.yamagata-u.ac.jp

Wataru Obara
watao@iwate-med.ac.jp

- ¹ Department of Urology, Iwate Medical University School of Medicine, 2-1-1 Idaidori, Yahaba-cho, Shiwa 028-3695, Japan
- ² Department of Urology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan
- ³ Department of Urology, Akita University School of Medicine, 1-1-1 Hondo, Akita 010-8543, Japan
- ⁴ Department of Urology and Advanced Blood Purification Therapy, Hirosaki University Graduate of Medicine, 5 Zaifuchou, Hirosaki 036-8562, Japan
- ⁵ Department of Urology, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima 960-1295, Japan
- ⁶ Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba 305-8575, Japan
- ⁷ Department of Urology, Tohoku University School of Medicine, 2-1 Seiryomachi, Aoba-ku, Sendai 980-8575, Japan
- ⁸ Department of Urology, Miyagi Cancer Center, 47-1, Nodayama, Shiote, Aijima, Natori 981-1293, Japan